As per DelveInsight’s assessment, globally, Cannabinoid pipeline constitutes 40+ key companies continuously working towards developing 50+ Cannabinoid treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Cannabinoids Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cannabinoid Market.
The Cannabinoid Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cannabinoid Pipeline Report:
- In May 2025, University of Massachusetts, Worcester conducted a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, or cannabis). Thirty-nine participants will be randomly assigned to switch to brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the control group). The study will be conducted at 4 sites in the US. The investigators expect to enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site. Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina at Chapel Hill (UNC).
- Companies across the globe are diligently working toward developing novel Cannabinoid treatment therapies with a considerable amount of success over the years.
- Cannabinoid companies working in the treatment market are Harmony Biosciences, Cardiol Therapeutics, SciSparc, Argent BioPharma, Ananda Pharma, BRC Therapeutics, Avata Biosciences, InMed Pharmaceuticals Inc., MIRA Pharmaceuticals Inc., Bionorica SE, Neurotech International, Botanix SB Inc., Octavian Therapeutics, ZYUS Life Sciences Corp., Avicanna Inc., Raphael Pharmaceutical, EPM Therapeutics, Polyrizon, Artelo Biosciences, Virpax Pharmaceuticals, and others, are developing therapies for the Cannabinoid treatment.
- Emerging Cannabinoid therapies in the different phases of clinical trials are ZYN002, MRX1, BRC-002, INM-901, CardiolRx, SCI-110, CannEpil, AVAT-021, MIRA-55, and others are expected to have a significant impact on the Cannabinoid market in the coming years.
- Cannabinoids are increasingly recognized for their therapeutic potential across oncology, neurology, pain management, and immunology, offering anti-inflammatory, neuroprotective, and anticancer effects.
- Innovations in synthetic formulations and drug delivery are enhancing their clinical efficacy and safety, solidifying cannabinoids as valuable tools in modern medicine.
Cannabinoids Overview
Cannabinoids are active chemical compounds found in Cannabis sativa and Cannabis indica plants or synthesized in laboratories, used to treat various medical conditions and symptoms. They interact with the body’s endocannabinoid system, which helps regulate key functions like pain, mood, appetite, and memory. These compounds have shown therapeutic potential in managing chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea.
Based on their origin, cannabinoids fall into three categories: Phytocannabinoids – naturally occurring in cannabis plants (e.g., THC, CBD), Endocannabinoids – produced by the human body (e.g., anandamide, 2-AG), and Synthetic cannabinoids – lab-created compounds, some of which are approved for medical use.
Get a Free Sample PDF Report to know more about Cannabinoid Pipeline Therapeutic Assessment: https://www.delveinsight.com/sample-request/cannabinoid-pipeline-insight
Emerging Cannabinoid Drugs Under Different Phases of Clinical Development Include:
- ZYN002: Harmony Biosciences
- MRX1: Ananda Pharma
- BRC-002: BRC Therapeutics
- INM-901: InMed Pharmaceuticals Inc.
- CardiolRx: Cardiol Therapeutics
- SCI-110: SciSparc
- CannEpil: Argent BioPharma
- AVAT-021: Avata Biosciences
- MIRA-55: MIRA Pharmaceuticals Inc.
- BX-1: Bionorica SE
- NTI164: Neurotech International
- BTX 1801: Botanix SB Inc.
- OCT130401: Octavian Therapeutics
- Trichomylin: ZYUS Life Sciences Corp.
- AVCN-319301a: Avicanna Inc.
- HPC1: Raphael Pharmaceutical
- EMP301: EPM Therapeutics
- SCI-160: Polyrizon
- ART 12.11: Artelo Biosciences
- NobrXiol: Virpax Pharmaceuticals
Cannabinoid Route of Administration
Cannabinoid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Cannabinoid Molecule Type
Cannabinoid Products have been categorized under various Molecule types, such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Cannabinoid Pipeline Therapeutics Assessment
- Cannabinoid Assessment by Product Type
- Cannabinoid By Stage and Product Type
- Cannabinoid Assessment by Route of Administration
- Cannabinoid By Stage and Route of Administration
- Cannabinoid Assessment by Molecule Type
- Cannabinoid by Stage and Molecule Type
DelveInsight’s Cannabinoid Report covers around 50+ products under different phases of clinical development like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Further Cannabinoid product details are provided in the report. Download the Cannabinoid pipeline report to learn more about the emerging Cannabinoid therapies: https://www.delveinsight.com/sample-request/cannabinoid-pipeline-insight
Some of the key companies in the Cannabinoid Therapeutics Market include:
Harmony Biosciences, Cardiol Therapeutics, SciSparc, Argent BioPharma, Ananda Pharma, BRC Therapeutics, Avata Biosciences, InMed Pharmaceuticals Inc., MIRA Pharmaceuticals Inc., Bionorica SE, Neurotech International, Botanix SB Inc., Octavian Therapeutics, ZYUS Life Sciences Corp., Avicanna Inc., Raphael Pharmaceutical, EPM Therapeutics, Polyrizon, Artelo Biosciences, Virpax Pharmaceuticals, and others.
Cannabinoid Pipeline Analysis:
The Cannabinoid pipeline report provides insights into:
- The report provides detailed insights about companies that are developing therapies for the treatment with Cannabinoids with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cannabinoid Treatment.
- Cannabinoid key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Cannabinoid Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cannabinoid market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cannabinoid drugs and therapies: https://www.delveinsight.com/sample-request/cannabinoid-pipeline-insight
Cannabinoid Pipeline Market Drivers
- Growing recognition of therapeutic potential across oncology, neurology, pain management, and immunology, continuous advancement in synthetic formulations and drug delivery technologies, increasing demand for safer alternatives to opioids for chronic pain management are some of the important factors that are fueling the Cannabinoid Market.
Cannabinoid Pipeline Market Barriers
- However, regulatory barriers, social stigma, high cost of drugs development, and varying legal frameworks across jurisdictions are creating obstacles in the Cannabinoid Market growth.
Scope of Cannabinoid Pipeline Drug Insight
- Coverage: Global
- Key Cannabinoid Companies: Harmony Biosciences, Cardiol Therapeutics, SciSparc, Argent BioPharma, Ananda Pharma, BRC Therapeutics, Avata Biosciences, InMed Pharmaceuticals Inc., MIRA Pharmaceuticals Inc., Bionorica SE, Neurotech International, Botanix SB Inc., Octavian Therapeutics, ZYUS Life Sciences Corp., Avicanna Inc., Raphael Pharmaceutical, EPM Therapeutics, Polyrizon, Artelo Biosciences, Virpax Pharmaceuticals, and others
- Key Cannabinoid Therapies: ZYN002, MRX1, BRC-002, INM-901, CardiolRx, SCI-110, CannEpil, AVAT-021, MIRA-55, BX-1, NTI164, BTX 1801, OCT130401, Trichomylin, AVCN-319301a, HPC1, EMP301, SCI-160, ART 12.11, NobrXiol, and others
- Cannabinoid Therapeutic Assessment: Cannabinoid current marketed and Cannabinoid emerging therapies
- Cannabinoid Market Dynamics: Cannabinoid market drivers and Cannabinoid market barriers
Table of Content
- Introduction
- Executive Summary
- Cannabinoids: Overview
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Cannabinoids – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Inactive Products
- Cannabinoids Key Companies
- Cannabinoids Key Products
- Cannabinoids – Unmet Needs
- Cannabinoids – Market Drivers and Barriers
- Cannabinoids – Future Perspectives and Conclusion
- Cannabinoids Analyst Views
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
